FDA Alerts: Medtronic Model 8637 SynchroMed II Implantable Infusion Pump
Monday 12 September 2011 at 2:20 pm September 12, 2011: The FDA reports that, for the Medtronic Model 8637 SynchroMed II Implantable Infusion Pump, there is a Class I Recall due to the potential for reduced battery performance that can lead to the sudden loss of therapy and the return of underlying symptoms and/or therapy withdrawal symptoms.FDA Alerts: Risperdal and Risperidone
Tuesday 21 June 2011 at 12:00 pm
Risperidone (Risperdal) and Ropinirole (Requip): Medication
Errors - Name Confusion
Healthcare Professionals reminded to clearly print or spell out the
medication name on prescriptions.
Risperdal (risperidone) and Risperidone: Recall -
Uncharacteristic Odor
Two lots recalled. Contamination thought to be the result of a
chemical preservative applied to wood used in the construction of
pallets on which materials are transported and stored.
Yaz / Yasmin Status Conference
Friday 26 March 2010 at 2:06 pmA status conference has been scheduled for April 14, 2010 at 9:00 a.m. before Judge David R. Herndon in the U.S. District Court, Southern District of Illinois. The conference is regarding the “Yasmin and Yaz (Drospirenone) Marketing, Sales Practice and Products Liability Litigation.” This multi-district litigation (MDL) consists of cases nationwide alleging serious injuries and deaths stemming from the use of Yaz or Yasmin birth control pills. A status conference is a pre-trial meeting where the attorneys inform the judge as to how the case is proceeding, what discovery has been completed, settlement negotiations that have occurred, and any other matters relevant to moving the case toward trial.
Posted March 26, 2010
By Cindy L. Nations
Trasylol Pretrial Conference
Friday 26 March 2010 at 1:15 pmA Pretrial Conference is scheduled for Thursday, April 1, 2010 at 1:30 p.m. before Judge Donald M. Middlebrooks in the U.S. District Court, Southern District of Florida, West Palm Beach Division. This is in the Trasylol multi-district litigation consisting of nation-wide lawsuits alleging kidney failure, heart attack, MI, stroke, and death resulting from the surgical drug Trasylol. The purpose of the conference is to discuss FDA issues.
Posted March 26, 2010
By Cindy L. Nations
